Progenics Pharmaceuticals — Merger or Acquisition (October 2019)
16 slides from Progenics Pharmaceuticals's merger presentation, Oct 2, 2019
Slide 1: Combination Creates a Leading Precision Diagnostics and Therapeutics Company
Exhibit 99.2 \s) Lantheus Progeni , Holdings « enics Combination Creates a Leading Precision Diagnostics and Therapeutics Company October 2, 2019
Slide 2: Safe Harbor Statements: Important Information For Investors And Stockholders
Safe Harbor Statements Important Information For Investors And Stockholders This document does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval in any jurisdiction in which such offer, solicitation or sale would be unlawf
Slide 3: Compelling Strategic Rationale
Compelling Strategic Rationale Robust portfolio and pipeline of precision diagnostic and therapeutic products Leadership with strong commercial, operational and financial expertise; aligned with stockholder interests Sustainable and diversified revenue growth with focus on commercial execution excel
Slide 4: Transaction Summary
Transaction Summary Lantheus Holdings to acquire 100% of Progenics’ common shares structured in a tax-free all-stock transaction Progenics stockholders to receive 0.2502 Lantheus Holdings shares for each Progenics share Implies 21.5% premium to Progenics’ 30-day volume weighted average closing stock
Slide 5: Lantheus' Three Growth Pillars to Enhance Long-Term Stockholder Value
Lantheus’ Three Growth Pillars to Enhance Long-Term Stockholder Value Enhance Core Enhance growth trajectory of core microbubble business Grow Externally Pursue selective transactions to support our growth Invest in emerging technologies within our pipeline Invest in Pipeline
Slide 6: Lantheus – Extensive Presence in the Radiopharmaceutical Industry
Lantheus – Extensive Presence in the Radiopharmaceutical Industry Supply Chain & Logistics Number of Radiopharmaceutical Suppliers Worldwide Highly Regulated — Local, State, Federal, & International Agencies Relationships with Radiopharmacies, Hospitals and Payers Product Development & Commercializa
Slide 7: Compelling Strategic Fit in Radiopharmaceuticals
First and Only FDA Approved Product for Ultra-Orphan Indications in Pheo and Para Additional Life Cycle Opportunties to Treat Other Neuroendocrine Tumor Types Late Stage PSMA Diagnostic Candidate and Promising Therapeutic Product Candidates Integrated PSMA Product Platform, Including AI, Addressing
Slide 8: Well-balanced Portfolio of Marketed Assets Spanning Diagnostics to Therapeutics
DEFINITY Benefits from unparalleled market and brand position Dedicated salesforce that drives advocacy and awareness Long-standing relationships with sonographers/echocardiologists New formulation has patent protection to 2035 Radiopharmaceuticals Cardiolite recognized as most widely-used diagnosti
Slide 9: Near-Term Value Creation Opportunities From this Transaction
Near-Term Value Creation Opportunities From this Transaction Ultra-Orphan radiotherapeutic Shown to help address the dual goals of treating advanced pheo / para: tumor reduction and symptom control Focused on delivering targeted solutions to address patients’ needs while creating significant value f
Slide 10: Robust Combined Pipeline with Clear Value Drivers
Legend: DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 FILING DEFINITY Octafluoropropane - Left Ventricular Ejection Fraction DEFINITY Octafluoropropane - Room Temperature Formulation Flurpiridaz F 18 PET Myocardial Perfusion Imaging LMI 1195 Flubrobenguane - Neuroendocrine Tumors in Pediatric / Adul
Slide 11: Strong Financial Outlook
Strong Financial Outlook Gross margin improvement potential through enhanced revenue growth and realizable cost savings and efficiencies Additional longer-term opportunities from diversified revenue / product mix Gross Margins Enhanced free cash flow with improved top line growth, operational execut
Slide 12: Combination Highlights
Robust portfolio and pipeline of precision diagnostic and therapeutic products Leadership with strong commercial, operational and financial expertise; aligned with stockholder interests Sustainable and diversified revenue growth with focus on commercial execution excellence Attractive financial prof
Slide 13: Appendix
APPENDIX = Laritttelis ] Holdings i Piven emcs
Slide 14: Lantheus Overview
Lantheus Overview #1 in Ultrasound Contrast Agents Innovating in Microbubble applications Across Microbubble and Radiopharmaceuticals Dynamic Pipeline Manufacturing, Supply Chain and Commercial Expertise Operational Excellence Leader in Radio- pharmaceuticals Pioneer in Radiopharmaceutical Diagnosti
Slide 15: Progenics Overview
Progenics Overview Company Overview Oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer Promising key pipeline products have potential to fuel long-term growth Therapeutic agents designed to precisely target cancer (1095 and PSMA TTC) PSMA-ta
Slide 16: Safe Harbor Statements: Cautionary Statement Regarding Forward-Looking Statements
Safe Harbor Statements Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties and are made pursuant to the safe harbor provision
Progenics Pharmaceuticals — Merger or Acquisition (October 2019) on 6ix